Status:
COMPLETED
Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Collaborating Sponsors:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Solid Tumor
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
This open-label, non-randomized trial will comprise of 2 parts. A dose escalation part will characterize the safety, biomarker and pharmacokinetics of OPB-111077 in advanced solid tumor. Subsequently,...
Detailed Description
This trial is designed to determine the safety, tolerability, maximum tolerated dose and recommended dose of OPB-111077 administered orally 4-days on and 3-days off (3 weeks/cycle) to subjects with ad...
Eligibility Criteria
Inclusion
- Pathologically and/or cytologically confirmed advanced solid tumor
- Patients who were refractory to standard therapy or for which there are no standard treatment options available
- Age 20 to 80 years at the time of informed consent
- Patients who, together with their partner, are willing and capable of using an appropriate method of contraception throughout the trial period and until at least 12 weeks after final IMP administration
- Patients informed of the diagnosis of advanced solid tumor who are fully informed about the content of the study by the investigator or subinvestigator using the specified written consent form and other written explanation, and give written consent to participate in the study of their free will
- Patients who are able to take oral medication
Exclusion
- Patients with symptomatic brain metastases
- Patients who have not recovered from any prior therapy related toxicity deemed to be clinically significant at study entry, except for the test item defined in inclusion criteria.
- Patients with active infections needing whole body therapy
- Patients with positive hepatitis B surface (HBs) antigen or positive hepatitis C virus (HCV) antibody
- Patients with positive human immunodeficiency virus (HIV) antibody
- Patients with uncontrollable cardiac diseases
- Patients with uncontrollable pain by analgesic drugs
- Patients with a history of organ transplantation
- Patients who have received another IMP
- Patients who are pregnant, possibly pregnant, or lactating
- Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Key Trial Info
Start Date :
October 23 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2019
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT02250170
Start Date
October 23 2014
End Date
March 8 2019
Last Update
September 10 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea
2
Seoul National University Bundang Hospital
Seoul, South Korea
3
Seoul National University Hospital
Seoul, South Korea